Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.45 |
| ▸ | ABAT | P80404 | 1/20 | 0.45 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.45 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2462903 | 0.81 | ALDH1A1 (0.58) | ALDH1A1MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL19214199 | 0.79 | TSHR (0.50) | ALDH1A1MAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL10477067 | 0.79 | ALDH1A1 (0.49) | ALDH1A1MAPTSMN1; SMN2HTTMEN1 | |
| SCHEMBL15331745 | 0.79 | ALDH1A1 (0.50) | ALDH1A1MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL19332292 | 0.78 | ALDH1A1 (0.57) | ALDH1A1MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL27841939 | 0.78 | MAPT (0.61) | ALDH1A1MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL20982802 | 0.77 | FDPS (0.42) | ALDH1A1HPGDLMNASMN1; SMN2HTT | |
| SCHEMBL22324340 | 0.77 | CA12 (0.39) | ALDH1A1MAPTHPGDSMN1; SMN2HTT | |
| SCHEMBL22324348 | 0.77 | TTR (0.45) | ALDH1A1MAPTSMN1; SMN2HTTTTR | |
| SCHEMBL29374370 | 0.77 | CA12 (0.39) | ALDH1A1MAPTHPGDSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114008065-B | Glycyrrhetinic acid derivatives for the treatment of hyperkalemia | 阿德利克斯股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | ARDELYX, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| CN-114008065-A | Glycyrrhetinic acid derivatives for treating hyperkalemia | 阿德利克斯股份有限公司 | 2022-02-01 | — | — | CN | disclosed |
| EP-3921327-A1 | GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA | Ardelyx, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020163642-A1 | GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | REN, NHERF1, KCNJ11 | ALDH1A1 1308/4885MAPT 3747/4885HPGD 1427/4885 |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | HSD11B2, HSD11B1, NR3C2 | ALDH1A1 822/4885MAPT 3972/4885HPGD 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.